The SUBITO trial (NCT02810743), in which stage III, HER2-negative, BRCA-altered breast cancer patients are treated with 4 cycles of ddAC and then randomized between neoadjuvant carboplatin/paclitaxel plus adjuvant olaparib versus high-dose carboplatin/thiotepa/cyclophosphamide, aims to provide answers to some of these questions. This evidence concerns the gene ERBB2 and breast carcinoma.